Objective To explore the changes of endostatin （a strong anti-angiogenesis factor） and vascular endothelial growth factor （VEGF） in the brain tissues of rabbits following cerebral ischemia induced by middle cerebr...Objective To explore the changes of endostatin （a strong anti-angiogenesis factor） and vascular endothelial growth factor （VEGF） in the brain tissues of rabbits following cerebral ischemia induced by middle cerebral artery occlusion （MCAO）. Methods Twenty-four New Zealand white rabbits were randomly divided into 5 groups： control （n = 5）, sham-operation （n = 4）, 2-hour ischemia （n = 5）, 24-hour ischemia （n = 5）, and 48-hour ischemia （n = 5）. The expression of VEGF and endostatin were measured by enzyme-linked immunosorbent assay （ELISA） and immunohistochemistry, respectively. In situ hybridization was used to characterize the expression of mRNA for the endostatin. Results Both the protein （at least 50%, P 〈 0.01） and mRNA （at least 70%, P 〈 0.05） of endostatin increased significantly in the ischemic brain tissues after MCAO compared with the control group. VEGF increased at least 270% in the brain after cerebral ischemia （P 〈 0.05）. Conclusion Cerebral ischemia leads to an up-regulation of endostatin in the brain, which is not associated with the increase of VEGF in the brain. The increase of endostatin may serve as a deleterious mechanism for ischemic injury through blocking angiogenesis.展开更多
Objective： The aim of this study was to compare effect of rh-endostatin on microvasculature in tumor and myocardium tissue. Methods： Nude mice were randomized into 4 groups, blank control group [did not burden tumor...Objective： The aim of this study was to compare effect of rh-endostatin on microvasculature in tumor and myocardium tissue. Methods： Nude mice were randomized into 4 groups, blank control group [did not burden tumor, normalsaline （NS） 100 μL/d], drug control group （did not burden tumor, rh-endostatin 400 μg/d）, model group （mice burdened tumor, NS 100 μL/d） and treatment group （mice burdened tumor, rh-endostatin 400 μg/d）, administration was given during d1-d28. The volume of tumor and the weight of mouse were measured before and after administration. The expression of CD34, MMP-2, MMP-9, HIF-la and VEGF in myocardium and tumor were detected by immunohistochemistry. The structure of vasculature was observed by immunoenzymatic double staining with CD34 and Masson. Results： The tumor volume increase of treatment group （48.18 mm3） was less than the model group （113.80 mm3）, the change of weight was not significant among the four groups. After treated with endotar, the expression of MMP-9 and VEGF in tumor were obviously down-regulated, but the same results was not found in MMP-2, HIF-la of tumor. MVD in tumor of treatment group decreased significantly compared with model group. Proportion of tumor vessels covered by collagen in treatment group increased compared with model group. However, MVD and microvasculature in myocardium did not change significantly. Conclusion： Rh-endostatin can decrease the expression of MMP-9, VEGF and MVD to inhibit growth of tumor and normalize micrangium in tumor but cannot weaken MMPs and MVD of mature micrangium in myocardium.展开更多
Objective To observe the effects of moxibustion therapy on the improvements of clinical symptom scale score and neuropeptide substance in vascular dementia （VD） and investigate a mechanism of moxibustion for VD. Met...Objective To observe the effects of moxibustion therapy on the improvements of clinical symptom scale score and neuropeptide substance in vascular dementia （VD） and investigate a mechanism of moxibustion for VD. Methods Eighty-seven cases of VD were divided randomly into a moxibustion group （43 cases） and a medication group （44 cases）. In moxibustion group, the isolated moxibustion with Typhonium Rhizome was applied to Baihui （百会 GV 20）, and suspended moxibustion was used on Shenting （神庭 GV 24） and Dazhui （大椎 GV 14）. In medication group, Piracetam tablet was taken orally. After 4-session treatment, the scores in Hasegawa＇s Dementia Scale （HDS）, Mini Mental Status Examination （MMSE） and Activity of Daily Living Scale （ADL） as well as the content of active substances, somatostatin （SS） and arginine vasopressin （AVP） in cerebral spinal fluid relevant with learning and memory were compared with those before treatment. Results The total effective rate was 81.4% （35/43） in moxibustion group, which was superior to 63.6% （28/44） in medication group （P〈0.01）. The scores in HDS, MMSE and ADL after treatment were all improved as compared with those before treatment in two groups （P〈0.05, P〈0.01）. The improvements of the scores in MMSE and ADL in moxibustion group were superior to those in medication group （both P〈0.05）. After treatment, SS and AVP content in cerebral spinal fluid increased remarkably as compared with those before treatment in two groups （both P〈0.01）, and SS and AVP levels after treatment in moxibustion group were improved significantly as compared with those in medication group （P〈0.05, P〈0.01）. Conclusion Moxibustion therapy is superior to oral administration of Piracetam tablet no matter in the improvement of symptom scores or in the regulation of neuropeptide substances relevant with learning and memory, which deserves to be promoted in application.展开更多
文摘Objective To explore the changes of endostatin （a strong anti-angiogenesis factor） and vascular endothelial growth factor （VEGF） in the brain tissues of rabbits following cerebral ischemia induced by middle cerebral artery occlusion （MCAO）. Methods Twenty-four New Zealand white rabbits were randomly divided into 5 groups： control （n = 5）, sham-operation （n = 4）, 2-hour ischemia （n = 5）, 24-hour ischemia （n = 5）, and 48-hour ischemia （n = 5）. The expression of VEGF and endostatin were measured by enzyme-linked immunosorbent assay （ELISA） and immunohistochemistry, respectively. In situ hybridization was used to characterize the expression of mRNA for the endostatin. Results Both the protein （at least 50%, P 〈 0.01） and mRNA （at least 70%, P 〈 0.05） of endostatin increased significantly in the ischemic brain tissues after MCAO compared with the control group. VEGF increased at least 270% in the brain after cerebral ischemia （P 〈 0.05）. Conclusion Cerebral ischemia leads to an up-regulation of endostatin in the brain, which is not associated with the increase of VEGF in the brain. The increase of endostatin may serve as a deleterious mechanism for ischemic injury through blocking angiogenesis.
基金Supported by grants from the Tianjin Medical University Research Projects(2009KY37)CSCO Vascular Target Fund Research Projects of Roche(Y-X2011-001)
文摘Objective： The aim of this study was to compare effect of rh-endostatin on microvasculature in tumor and myocardium tissue. Methods： Nude mice were randomized into 4 groups, blank control group [did not burden tumor, normalsaline （NS） 100 μL/d], drug control group （did not burden tumor, rh-endostatin 400 μg/d）, model group （mice burdened tumor, NS 100 μL/d） and treatment group （mice burdened tumor, rh-endostatin 400 μg/d）, administration was given during d1-d28. The volume of tumor and the weight of mouse were measured before and after administration. The expression of CD34, MMP-2, MMP-9, HIF-la and VEGF in myocardium and tumor were detected by immunohistochemistry. The structure of vasculature was observed by immunoenzymatic double staining with CD34 and Masson. Results： The tumor volume increase of treatment group （48.18 mm3） was less than the model group （113.80 mm3）, the change of weight was not significant among the four groups. After treated with endotar, the expression of MMP-9 and VEGF in tumor were obviously down-regulated, but the same results was not found in MMP-2, HIF-la of tumor. MVD in tumor of treatment group decreased significantly compared with model group. Proportion of tumor vessels covered by collagen in treatment group increased compared with model group. However, MVD and microvasculature in myocardium did not change significantly. Conclusion： Rh-endostatin can decrease the expression of MMP-9, VEGF and MVD to inhibit growth of tumor and normalize micrangium in tumor but cannot weaken MMPs and MVD of mature micrangium in myocardium.
基金Supported by Projects of Natural Science Foundation of Anhui Province: 30430070
文摘Objective To observe the effects of moxibustion therapy on the improvements of clinical symptom scale score and neuropeptide substance in vascular dementia （VD） and investigate a mechanism of moxibustion for VD. Methods Eighty-seven cases of VD were divided randomly into a moxibustion group （43 cases） and a medication group （44 cases）. In moxibustion group, the isolated moxibustion with Typhonium Rhizome was applied to Baihui （百会 GV 20）, and suspended moxibustion was used on Shenting （神庭 GV 24） and Dazhui （大椎 GV 14）. In medication group, Piracetam tablet was taken orally. After 4-session treatment, the scores in Hasegawa＇s Dementia Scale （HDS）, Mini Mental Status Examination （MMSE） and Activity of Daily Living Scale （ADL） as well as the content of active substances, somatostatin （SS） and arginine vasopressin （AVP） in cerebral spinal fluid relevant with learning and memory were compared with those before treatment. Results The total effective rate was 81.4% （35/43） in moxibustion group, which was superior to 63.6% （28/44） in medication group （P〈0.01）. The scores in HDS, MMSE and ADL after treatment were all improved as compared with those before treatment in two groups （P〈0.05, P〈0.01）. The improvements of the scores in MMSE and ADL in moxibustion group were superior to those in medication group （both P〈0.05）. After treatment, SS and AVP content in cerebral spinal fluid increased remarkably as compared with those before treatment in two groups （both P〈0.01）, and SS and AVP levels after treatment in moxibustion group were improved significantly as compared with those in medication group （P〈0.05, P〈0.01）. Conclusion Moxibustion therapy is superior to oral administration of Piracetam tablet no matter in the improvement of symptom scores or in the regulation of neuropeptide substances relevant with learning and memory, which deserves to be promoted in application.
